Title :

Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders

Author(s) :

Jannin, Arnaud [Auteur]
Service Endocrinologie, diabétologie, maladies métaboliques et nutrition [LILLE - Endocrino]
Penel, Nicolas [Auteur]
Service d'oncologie médicale (CHRU Lille)
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] [UNICANCER/Lille]
Ladsous, Miriam [Auteur]
Service Endocrinologie, diabétologie, maladies métaboliques et nutrition [LILLE - Endocrino]
Vantyghem, Marie-Christine [Auteur]
Service Endocrinologie, diabétologie, maladies métaboliques et nutrition [LILLE - Endocrino]
Recherche translationnelle sur le diabète (RTD) - U1190
Do Cao, Christine [Auteur]
Service Endocrinologie, diabétologie, maladies métaboliques et nutrition [LILLE - Endocrino]

Journal title :

Critical Reviews in Oncology/Hematology

Volume number :

141

Pages :

23-35

Publisher :

Elsevier

Publication date :

2019-09

ISSN :

10408428

English keyword(s) :

Thyroiditis
Tyrosine kinase inhibitors
Immunotherapy
Immune checkpoint inhibitors
toxicity
thyrotoxicosis
hypothyroidism

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Recently, tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICPIs) have emerged as new classes of anticancer therapies. Although generally considered less toxic than cytotoxic chemotherapy, these new drugs ...
Show more >Recently, tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICPIs) have emerged as new classes of anticancer therapies. Although generally considered less toxic than cytotoxic chemotherapy, these new drugs can cause significant unanticipated side effects including thyroid dysfunction. This review provides a literature assessment of thyroid dysfunctions induced by TKI and ICPIs. We intend to define for these two classes the frequency of thyroid involvement, the potential mechanisms that result in this toxicity, the clinical-biological impact and the therapeutic management. Detection of thyroid dysfunction requires monitoring of TSH, in combination with free T4 if needed and, depending on the clinical impact and the kinetics of biological abnormalities, starting symptomatic treatment of hyperthyroidism and/or correcting hypothyroidism.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
• Recherche translationnelle sur le diabète (RTD) - U1190

Submission date :

2021-12-08T09:53:54Z
2024-04-30T11:02:58Z